GE91 Stock Overview
Develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for GE91 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Genmab A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 19.00 |
| 52 Week High | DKK 29.80 |
| 52 Week Low | DKK 19.00 |
| Beta | 0.87 |
| 1 Month Change | -2.56% |
| 3 Month Change | -17.39% |
| 1 Year Change | -33.57% |
| 3 Year Change | -45.40% |
| 5 Year Change | n/a |
| Change since IPO | -30.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| GE91 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -8.7% | -1.2% | -1.4% |
| 1Y | -33.6% | -13.2% | 8.0% |
Return vs Industry: GE91 underperformed the German Biotechs industry which returned -12.8% over the past year.
Return vs Market: GE91 underperformed the German Market which returned 8.1% over the past year.
Price Volatility
| GE91 volatility | |
|---|---|
| GE91 Average Weekly Movement | 4.1% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: GE91 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: GE91's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 2,635 | Jan G.J. de Winkel | www.genmab.com |
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies.
Genmab A/S Fundamentals Summary
| GE91 fundamental statistics | |
|---|---|
| Market cap | €12.66b |
| Earnings (TTM) | €630.26m |
| Revenue (TTM) | €2.66b |
20.1x
P/E Ratio4.8x
P/S RatioIs GE91 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GE91 income statement (TTM) | |
|---|---|
| Revenue | DKK 19.84b |
| Cost of Revenue | DKK 774.00m |
| Gross Profit | DKK 19.07b |
| Other Expenses | DKK 14.37b |
| Earnings | DKK 4.70b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 74.02 |
| Gross Margin | 96.10% |
| Net Profit Margin | 23.69% |
| Debt/Equity Ratio | 0% |
How did GE91 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 09:37 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Genmab A/S is covered by 45 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew Carlsen | ABG Sundal Collier |
| Armelle Moulin | AlphaValue |
| Emily Field | Barclays |